These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21665542)

  • 41. Anti-Müllerian hormone: a better marker of ovarian damage from cyclophosphamide.
    Clowse ME; Harward L; Criscione-Schreiber L; Pisetsky D; Copland S
    Arthritis Rheum; 2012 May; 64(5):1305-10. PubMed ID: 22354568
    [No Abstract]   [Full Text] [Related]  

  • 42. Prognosis and cost-effectiveness of IVF in poor responders according to the Bologna Criteria.
    Busnelli A; Somigliana E
    Minerva Ginecol; 2018 Feb; 70(1):89-98. PubMed ID: 28895678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient-tailored ovarian stimulation for in vitro fertilization.
    Fauser BCJM
    Fertil Steril; 2017 Oct; 108(4):585-591. PubMed ID: 28965553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.
    Yates AP; Roberts SA; Nardo LG
    Hum Reprod; 2012 Feb; 27(2):629. PubMed ID: 22114109
    [No Abstract]   [Full Text] [Related]  

  • 45. Can stimulation protocols improve oocyte quality?
    Smitz J
    Ernst Schering Res Found Workshop; 2002; (41):161-75. PubMed ID: 12402545
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacogenomics in IVF: A New Era in the Concept of Personalized Medicine.
    Kalinderi K; Asimakopoulos B; Nikolettos N; Manolopoulos VG
    Reprod Sci; 2019 Oct; 26(10):1313-1325. PubMed ID: 29587614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA methylation-based age prediction and telomere length in white blood cells and cumulus cells of infertile women with normal or poor response to ovarian stimulation.
    Morin SJ; Tao X; Marin D; Zhan Y; Landis J; Bedard J; Scott RT; Seli E
    Aging (Albany NY); 2018 Dec; 10(12):3761-3773. PubMed ID: 30530921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant follicle-stimulating hormone and luteinizing hormone--mimicking nature and beyond.
    McDonough PG
    Fertil Steril; 1995 Jul; 64(1):211-2. PubMed ID: 7789565
    [No Abstract]   [Full Text] [Related]  

  • 49. Regulation of ovarian androgen production: a key parameter to success during ovarian stimulation?
    Andersen CY
    Hum Reprod; 1995 Sep; 10(9):2227-33. PubMed ID: 8530641
    [No Abstract]   [Full Text] [Related]  

  • 50. The ever-rising spiral of technology and cost.
    Chetkowski RJ
    Fertil Steril; 2006 Aug; 86(2):497; author reply 497. PubMed ID: 16892491
    [No Abstract]   [Full Text] [Related]  

  • 51. The Bologna criteria for poor ovarian response; has the job been accomplished?
    Younis JS
    Hum Reprod; 2012 Jun; 27(6):1874-5; author reply 1875-6. PubMed ID: 22473398
    [No Abstract]   [Full Text] [Related]  

  • 52. The end for individualized dosing in IVF ovarian stimulation? Reply to letters-to-the-editor regarding the OPTIMIST papers.
    van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Mol BW; Broekmans FJM;
    Hum Reprod; 2018 May; 33(5):984-988. PubMed ID: 29596576
    [No Abstract]   [Full Text] [Related]  

  • 53. Why delay the obvious need for milder forms of ovarian stimulation?
    Edwards RG; Lobo RA; Bouchard P
    Hum Reprod; 1997 Feb; 12(2):399-401. PubMed ID: 9070738
    [No Abstract]   [Full Text] [Related]  

  • 54. Time to revolutionize ovarian stimulation. Ovarian stimulation.
    Fleming R
    Hum Reprod; 1996 Dec; 11(12):2579. PubMed ID: 9021353
    [No Abstract]   [Full Text] [Related]  

  • 55. Is progress in clinical reproductive medicine happening fast enough?
    Griesinger G
    Ups J Med Sci; 2020 May; 125(2):65-67. PubMed ID: 32364444
    [No Abstract]   [Full Text] [Related]  

  • 56. The definition of 'poor response': Bologna criteria.
    Sallam HN; Ezzeldin F; Agameya AF; Abdel-Rahman AF; El-Garem Y
    Hum Reprod; 2012 Feb; 27(2):626-7; author reply 627-8. PubMed ID: 22114113
    [No Abstract]   [Full Text] [Related]  

  • 57. Gone and forgotten: where has the "literature" gone?
    Albertini DF
    J Assist Reprod Genet; 2012 May; 29(5):373-4. PubMed ID: 22532051
    [No Abstract]   [Full Text] [Related]  

  • 58. Precocious ovarian stimulation following interruption of stria terminalis.
    ELWERS M; CRITCHLOW V
    Am J Physiol; 1961 Aug; 201():281-4. PubMed ID: 13726571
    [No Abstract]   [Full Text] [Related]  

  • 59. #ESHREjc report: ovarian stimulation practice after the OPTIMIST trial and evidence-based medicine.
    Makieva S; Massarotti C; Uraji J; Serdarogullari M; Fraire-Zamora JJ; Ali ZE; Liperis G; Vassena R; Wang R; Bortoletto P; Ammar OF
    Hum Reprod; 2021 Sep; 36(10):2808-2810. PubMed ID: 34293144
    [No Abstract]   [Full Text] [Related]  

  • 60. The promised land of individualized ovarian stimulation: Are we there yet?
    Kim HH; Speedy SE
    Fertil Steril; 2021 Apr; 115(4):893-894. PubMed ID: 33832745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.